Survey of activated FLT3 signaling in leukemia.
Activating mutations of FMS-like tyrosine kinase-3 (FLT3) are found in approximately 30% of patients with acute myeloid leukemia (AML). FLT3 is therefore an attractive drug target. However, the molecular mechanisms by which FLT3 mutations lead to cell transformation in AML remain unclear. To develop...
Guardado en:
Autores principales: | Ting-lei Gu, Julie Nardone, Yi Wang, Marc Loriaux, Judit Villén, Sean Beausoleil, Meghan Tucker, Jon Kornhauser, Jianmin Ren, Joan MacNeill, Steven P Gygi, Brian J Druker, Michael C Heinrich, John Rush, Roberto D Polakiewicz |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1023d0cf89bb45dc84d23254aa8bce3c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia
por: Andoni Garitano-Trojaola, et al.
Publicado: (2021) -
Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells
por: Jonathan Metts, et al.
Publicado: (2017) -
The correlation between Flt3-ITD mutation in dendritic cells with TIM-3 expression in acute myeloid leukemia
por: Hooriyeh Shapoorian, et al.
Publicado: (2021) -
Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines
por: Varvara Maiorova, et al.
Publicado: (2021) -
FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells
por: Kouhei Yamawaki, et al.
Publicado: (2021)